SeproxetineAlternative Names: LY 215229; Norfluoxetine
Latest Information Update: 10 Sep 1998
At a glance
- Originator Eli Lilly
- Class Propylamines
- Mechanism of Action Serotonin uptake inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 10 Sep 1998 No-Development-Reported for Depression (PO)
- 09 Jan 1997 Preclinical development for Depression (PO)
- 20 Feb 1996 New profile